SEARCH

SEARCH BY CITATION

References

  • 1
    Yeoh J, Williams C, Allen P et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36: 44954.
  • 2
    Ghosh S, Singh D, Ruddle J, Shiu M, Coote M, Crowston J. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma. Clin Experiment Ophthalmol 2010; 38: 3537.
  • 3
    Sheth S, Rush R, Natarajan S, Gillies M. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clin Experiment Ophthalmol 2011; 39: 673681.
  • 4
    Quian J, Lu Q, Tao Y, Jiang Y. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011; 31: 1618.
  • 5
    Curtis L, Hammill B, Schulman K, Cousins S. Risks of mortality, myocardial infarction, bleeding and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 12739.
  • 6
    Martin D, Maguire M, Gui-shuang Y, Grunwald J, Fine S, Jaffe G. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897908.
  • 7
    Chakravarthy U, Wong T, Fletcher A et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010. Accessed October 31, 2011. Available from: http://www.medscape.com/viewarticle/735166
  • 8
    Franks P, Clancy C, Gold M. Health insurance and mortality. JAMA 1993; 270: 73741.
  • 9
    Beaumont P. Bevacizumab: not as good with more adverse reactions? Clin Experiment Ophthalmol 2011; 39: 58890.
  • 10
    Martin D, Maguire M, Fine S. Bevacizumab: not as good with more adverse reactions? Response. Clin Experiment Ophthalmol 2011; 39: 71820.
  • 11
    Gower E, Cassard S, Chu L, Varma R, Klein R. Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration. The Association for Vision Research in Ophthalmology: presentation 6644. Fort Lauderdale, USA, 2011.
  • 12
    Pollack A. Avastin injections are reported to cause blindness. New York Times 2011.